Compounds which inhibit or antagonize the biosynthesis or actions of androgens.
|Drug||Drug Name||Drug Indication|
|DB04839||Cyproterone acetate||For the palliative treatment of patients with advanced prostatic carcinoma.|
|DB00499||Flutamide||For the management of locally confined Stage B2-C and Stage D2 metastatic carcinoma of the prostate|
|DB00665||Nilutamide||For use in combination with surgical castration for the treatment of metastatic prostate cancer involving distant lymph nodes, bone, or visceral organs (Stage D2).|
|DB01128||Bicalutamide||For treatment (together with surgery or LHRH analogue) of advanced prostatic cancer.|
|DB08899||Enzalutamide||Enzalutamide is indicated for the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel.|
|DB11901||Apalutamide||Indicated for the treatment of patients with non-metastatic, castration-resistant prostate cancer (NM-CRPC) [FDA Label].|